Should You Buy the Dip in Tilray?

: TLRY | Tilray Brands Inc. Cl 2 News, Ratings, and Charts

TLRY – Canada-based cannabis producer Tilray’s (TLRY) acquisition strategy could drive its long-term growth. However, the company’s shares have fallen in price significantly over the past six months. Uncertainty surrounding the decriminalization of marijuana in the United States has caused investors to pull back from pot stocks. Furthermore, considering TLRY’s weak bottom line, is the stock a buy in the recent dip? Keep reading.

Nanaimo, Canada-based Cannabis producer Tilray, Inc. (TLRY) researches, cultivates, produces, markets, and distributes medical cannabis products. The company has executed some prominent mergers this year to strengthen its global presence. Its acquisition of Aphria (APHA) is expected to help it grow significantly. It intends to create a leading cannabis-focused consumer packaged goods (CPG) company with the largest global geographic footprint in the industry. Also, in the summer, TLRY acquired a majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc., a premier American cannabis retailer.

Given that a new Congressional Republican-led marijuana legalization bill has been introduced in Congress, TLRY’s recent acquisitions should prove beneficial. Recently, Congresswoman Nancy Mace (R-SC) introduced a bill to decriminalize marijuana, with a majority of Americans now in favor of such a policy. If the U.S market opens for business fully, TLRY should be able to expand its market reach and improve its operational capabilities. However, things are moving at a slow pace, and it could be some time before TLRY can acquire a larger market share. Also, the company’s weak bottom line is a concern. Also, Barclays’ analysts have noted that the legislation is unlikely to happen under the Biden administration. Barclays also stated that Canadian cannabis companies would struggle to compete with U.S. multistate operators.

TLRY’s stock performance over the past six months has been sluggish. Its shares have fallen substantially over the past six months. Moreover, the stock is trading below its 50-day and 200-day moving averages. In addition, the stock slumped in price last week. Investors are pulling back from pot stocks due to doubts surrounding the legalization of cannabis at the Federal level. Also, the stock has a 1.52 beta, indicating high volatility.

Click here to check out our Cannabis Industry Report for 2021

Here is what could shape TLRY’s performance in the near term:

Mixed Profitability

TLRY’s 24.70% gross profit margin is 55.3% lower than the 55.21% industry average Also, its negative 18.72% EBIT margin is substantially lower than the industry average.

However, TLRY’s negative 13.14%, 6.26%, and 1.88% respective ROE, ROA, and ROTC compare with the negative 34.82%, 21.97%, and 18.30% industry averages.

Weak Bottom-Line

TLRY’s net revenues increased 43% year-over-year to $168.02 million in its fiscal first quarter, ended August 31. However, its operating loss stood at $68.53 million, up 709% from the same period last year. Its net loss grew 59% from its year-ago value to $34.60 million. The company’s loss per share came in at $0.08, indicating a marginal decline from the prior-year quarter. Also, its trailing-12-months EBITDA was negative $9.31 million.

POWR Ratings Reflect This Bleak Prospects

TLRY has an overall D rating which translates to Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.

The stock has a grade of D for Stability, consistent with its high beta.

TLRY has a D grade for Momentum. This is justified because the stock is trading below its 50-day and 200-day moving averages.

Of the 198 stocks in the F-rated Medical – Pharmaceuticals industry, TLRY is ranked #170.

Beyond what I have stated above, one can also view TLRY’s grades for Sentiment, Growth, Value, and Quality here.

View the top-rated stocks in the Medical – Pharmaceuticals industry here.

Bottom Line

TLRY is one of the top cannabis producers in Canada and is expected to grow significantly in the long term, considering its recent strategic mergers to strengthen its global footprint. However, the company has a long way to go before it hits its goal of becoming a global leader. Its weak bottom line could be a concern. Moreover, analysts expect its EPS to remain negative at least until next year. Also, given its high volatility, we think TLRY is better avoided now.

How Does Tilray, Inc. (TLRY) Stack Up Against its Peers?

While TLRY has an overall POWR Rating of D, one might want to consider investing in the following Medical – Pharmaceuticals stocks with an A (Strong Buy) rating: Johnson & Johnson (JNJ), Merck & Co. Inc. (MRK), and GlaxoSmithKline PLC (GSK).

Click here to check out our Cannabis Industry Report for 2021


TLRY shares fell $0.47 (-4.31%) in premarket trading Friday. Year-to-date, TLRY has gained 31.96%, versus a 26.79% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TLRYGet RatingGet RatingGet Rating
JNJGet RatingGet RatingGet Rating
MRKGet RatingGet RatingGet Rating
GSKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Should Investors BEWARE this Market?

The S&P 500 (SPY) has been on a tear since November 1st when the Fed started to make their dovish tilt opening the door to future rate cuts. Unfortunately they keep not happening and start date keeps getting pushed further and further out. That has many wondering if stocks are getting ahead of themselves setting things up for a fall. Thus a good time to tune into what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Is the Bull Market Growing Tired?

On the one hand it is fun to celebrate the new highs for the S&P 500 (SPY) that came in this Tuesday. On the other hand...it doesn’t make a lot of sense calling into question the next moves for the stock market. Read on below to appreciate investment veteran, Steve Reitmeister’s, market outlook and top picks to outperform.

Read More Stories

More Tilray Brands Inc. Cl 2 (TLRY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TLRY News